The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats

Treatment with the anti-CGRP antibody fremanezumab is successful in the prevention of chronic and frequent episodic migraine. In preclinical rat experiments, fremanezumab has been shown to reduce calcitonin gene-related peptide (CGRP) release from trigeminal tissues and aversive behaviour to noxious...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogler, Birgit, Kuhn, Annette, Mackenzie, Kimberly D., Stratton, Jennifer, Dux, Mária, Messlinger, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487893/
https://www.ncbi.nlm.nih.gov/pubmed/37686275
http://dx.doi.org/10.3390/ijms241713471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487893/
https://www.ncbi.nlm.nih.gov/pubmed/37686275
http://dx.doi.org/10.3390/ijms241713471

Ejemplares similares